Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2016 07:37 ET | Source: Novartis Pharma AG

Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors

If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional...
April 27, 2016 01:15 ET | Source: Novartis Pharma AG

Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential...
April 21, 2016 01:00 ET | Source: Novartis Pharma AG

Novartis a enregistré un premier trimestre solide, malgré la perte d'exclusivité de Gleevec, et investi dans de nouveaux lancements pour soutenir la croissance à long terme

Chiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9...
April 21, 2016 01:00 ET | Source: Novartis Pharma AG

Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums

Der Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34% des...
April 21, 2016 01:00 ET | Source: Novartis Pharma AG

Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow...
April 20, 2016 12:00 ET | Source: Novartis Pharma AG

Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most common...
April 08, 2016 01:15 ET | Source: Novartis Pharma AG

Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication

Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community ...
April 07, 2016 01:15 ET | Source: Novartis Pharma AG

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP

EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily...
April 02, 2016 11:00 ET | Source: Novartis Pharma AG

Neue Analysen zeigen, dass Entresto(TM) von Novartis das Risiko für kardiovaskulären Tod oder Hospitalisierung wegen Herzinsuffizienz reduzierte und Patienten mit reduzierter Ejektionsfraktion...

Neue Analysen zeigen, dass Entresto(TM) von Novartis das Risiko für kardiovaskulären Tod oder Hospitalisierung wegen Herzinsuffizienz reduzierte und Patienten mit reduzierter Ejektionsfraktion...
April 02, 2016 11:00 ET | Source: Novartis Pharma AG

New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...

New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart...